Results 171 to 180 of about 209,011 (190)

HIV Protease Inhibitors

2007
openaire   +2 more sources

HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma

Nature Medicine, 2002
C. Sgadari, G. Barillari, E. Toschi, D. Carlei, I. Bacigalupo, S. Baccarini, C. Palladino, P. Leone, R. Bugarini, L. Malavasi, A. Cafaro, M. Falchi, D. Valdembri, G. Rezza, F. Bussolino, P. Monini, B. Ensoli   +16 more
semanticscholar   +1 more source

HIV protease inhibitors

Reactions Weekly, 2006
openaire   +1 more source

Oral Thrush and HIV Protease Inhibitors

Journal of Acquired Immune Deficiency Syndromes, 1999
R B, Stricker, B, Goldberg
openaire   +2 more sources

Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands

Bioorganic and Medicinal Chemistry Letters, 2015
Arun K Ghosh, Yuan-Fang Wang, Masayuki Amano   +2 more
exaly  

HIV protease inhibitors

2014
Kuhnert, Maren, Diederich , Wibke E.
openaire   +1 more source

Pravastatin in HIV-Infected Patients Treated with Protease Inhibitors: A Placebo-Controlled Randomized Study

HIV Clinical Trials, 2007
Dominique Breilh, Rodolphe Thiébaut, François Dabis   +2 more
exaly  

HIV protease inhibitors block adipogenesis and increase lipolysis in vitro.

Antiviral Research, 2000
J. Lenhard, E. Furfine, Renu G Jain, O. Ittoop, L. Orband-Miller, S. Blanchard, M. Paulik, J. Weiel   +7 more
semanticscholar   +1 more source

Design, synthesis and biological evaluation of novel HIV-1 protease inhibitors with pentacyclic triterpenoids as P2-ligands

Bioorganic and Medicinal Chemistry Letters, 2019
Mei Zhu, Guoning Zhang, Ju-Xian Wang
exaly  

Risk-benefit of HMG-CoA reductase inhibitors in the treatment of HIV protease inhibitor-related hyperlipidaemia

Expert Opinion on Drug Safety, 2002
Scott R Penzak
exaly